Iridocyclitis

Summary

Iridocyclitis (MONDO:0004773) is a disease and 3 clinical trials. Top therapeutic interventions include diclofenac. A subtype of ciliary body disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	iridocyclitis
Mondo ID	MONDO:0004773
MeSH	D015863
DOID	DOID:9383
ICD-10-CM	H20
NCIT	C34736
SNOMED CT	77971008
UMLS	C0022073
MedGen	43961
GARD	0024102
Is cancer (heuristic)	no

Also known as: iridocyclitis · iridocyclitis (disease) · primary iridocyclitis

Data availability: 1 HPO phenotype.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › iris disorder › ciliary body disorder › iridocyclitis

Related subtypes (2): pars planitis, ciliary body neoplasm

Subtypes (3): glaucomatocyclitic crisis, lens-induced iridocyclitis, infectious anterior uveitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cortisone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00006188	Not specified	COMPLETED	Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00476593	Not specified	COMPLETED	Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
NCT03753893	Not specified	COMPLETED	Ocular Manifestations in Rheumatic Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DICLOFENAC	4	1